| Active Ingredient: | Saroglitazar |
|---|---|
| Indication: | Non-alcoholic Fatty Liver Disease |
| Manufacturer: | Zydus Lifesciences |
| Packaging: | 15 Tablets in strip |
| Strength: | 4mg |
| Delivery Time: | 6 To 15 days |
Saroglitazar 4 mg | ||||
|---|---|---|---|---|
| 4mg | Price | Price/unit | Qty | Cart |
| 45 Tablet/s | AUD$70.20 | AUD$1.56/Tablet | ||
| 90 Tablet/s | AUD$124.80 | AUD$1.39/Tablet | ||
| 180 Tablet/s | AUD$226.20 | AUD$1.26/Tablet | ||
Saroglitazar 4 mg Tablet is a prescription medication used primarily to treat diabetic dyslipidemia and hypertriglyceridemia, particularly in individuals with type 2 diabetes mellitus. It belongs to a novel class of drugs known as dual PPAR (peroxisome proliferator-activated receptor) agonists. These receptors help regulate lipid metabolism and glucose homeostasis, making Saroglitazar effective in managing blood sugar and lipid levels.
Unlike traditional lipid-lowering agents, Saroglitazar targets both high triglycerides and insulin resistance, offering a two-pronged approach to metabolic control. It is particularly beneficial for patients who are unable to achieve target lipid levels with statins alone. Saroglitazar is taken orally and is generally well-tolerated with minimal side effects in most users.
The drug is gaining recognition for its potential benefits in treating liver disorders such as non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH), as it improves liver enzymes and reduces fat accumulation in the liver. Always use it under medical supervision for optimal results and safety.
Saroglitazar 4 mg stands out as an innovative therapy in the management of metabolic disorders. Approved in India, it is especially effective in treating diabetic dyslipidemia, a common and serious complication of type 2 diabetes characterized by elevated triglycerides and reduced HDL cholesterol.
Its mechanism involves dual activation of PPAR-α and PPAR-γ receptors. This dual action enables the drug to regulate lipid levels (via PPAR-α) and improve insulin sensitivity (via PPAR-γ). Such combined effects address the root metabolic dysfunctions seen in type 2 diabetes and metabolic syndrome.
Recent studies have highlighted its role in improving liver function, making it a promising treatment for NAFLD and NASH. Saroglitazar has shown the potential to reduce ALT and AST enzyme levels, liver fat content, and inflammation, making it an attractive candidate for patients with diabetes and concurrent liver disease.
Unlike fibrates or thiazolidinediones, Saroglitazar has a lower risk of weight gain or fluid retention. However, regular liver function tests and lipid profiles are advised to monitor progress and ensure safety. This drug is typically taken once daily after a meal, with or without statins, based on the doctor’s advice.
Saroglitazar 4 mg begins to show noticeable therapeutic effects within 4 to 12 weeks of regular use. In clinical trials and real-world patient reports, improvements in lipid profiles—especially triglyceride levels—can be observed as early as 4 weeks, with sustained and enhanced benefits seen over the following weeks.
For patients with elevated liver enzymes or fatty liver, reductions in liver enzymes like ALT and AST may be evident within 8 to 12 weeks. These improvements indicate reduced liver inflammation and fat accumulation.
It’s important to understand that the speed of effectiveness can vary depending on the individual’s overall health, severity of dyslipidemia, insulin resistance, and adherence to the prescribed regimen. For optimal results, it’s crucial to maintain a healthy diet, exercise regularly, and monitor glucose levels if diabetic.
While the lipid-lowering effect is relatively quick, liver benefits often require a longer duration of treatment, typically several months. Consistent monitoring of lipid profiles and liver enzymes is recommended during treatment.
Patients should not expect instant results within a few days, but can anticipate steady progress with continued use. Always follow up with your healthcare provider for personalized guidance and assessment.
The recommended dosage of Saroglitazar is typically 4 mg once daily, taken orally with or without food. The tablet should be swallowed whole with water and not crushed or chewed. Taking it at the same time each day helps maintain consistent drug levels in the body and maximizes its therapeutic effects.
For most adults, especially those with diabetic dyslipidemia or hypertriglyceridemia, the 4 mg dose is sufficient to manage both lipid levels and insulin resistance. Your doctor may adjust the dose based on your specific condition, treatment goals, and response to therapy.
It is essential to follow the prescribed dosage exactly as directed by your healthcare provider. Do not increase or decrease the dose on your own. Skipping doses or inconsistent use may reduce the effectiveness of the treatment.
Monitoring of lipid panels, liver function tests, and glucose levels is recommended during treatment. If you miss a dose, take it as soon as you remember, unless it’s near the time of the next dose. In that case, skip the missed dose—do not double it.
Saroglitazar 4 mg helps treat liver diseases like NAFLD (non-alcoholic fatty liver disease) and NASH (non-alcoholic steatohepatitis) by reducing liver fat accumulation, inflammation, and improving liver enzyme levels. It does so by activating both PPAR-α and PPAR-γ receptors.
Activation of PPAR-α helps reduce triglycerides and enhances fat metabolism in the liver, leading to a reduction in hepatic steatosis (fatty liver). PPAR-γ activation improves insulin sensitivity and reduces liver inflammation, which is critical in slowing or reversing liver damage.
Clinical studies have shown significant improvement in liver enzyme markers such as ALT, AST, and GGT after treatment with Saroglitazar. These enzymes, when elevated, indicate liver inflammation or injury.
By addressing the underlying metabolic dysfunctions—especially lipid metabolism and insulin resistance—Saroglitazar offers a holistic approach to treating Liver Disease associated with metabolic syndrome or type 2 diabetes.
| Benefit | Description |
|---|---|
| Lowers Triglycerides | Significantly reduces high triglyceride levels in diabetic patients. |
| Improves Insulin Sensitivity | Helps improve blood glucose control in type 2 diabetes. |
| Liver Health Support | Reduces fat accumulation in the liver and improves liver enzymes (ALT, AST). |
| Dual Action Mechanism | Combines PPAR-α and PPAR-γ activation for metabolic regulation. |
| Minimal Side Effects | Generally well-tolerated with fewer adverse reactions compared to older drugs. |
| Cardiovascular Benefits | May reduce cardiovascular risks associated with dyslipidemia. |
| Weight Neutral | Unlike other PPAR-γ drugs, Saroglitazar doesn’t usually cause weight gain. |
| Once-Daily Dosage | Convenient to use, supports patient adherence. |
| Potential NASH Therapy | Promising option in early treatment of non-alcoholic steatohepatitis. |
| Can Be Combined with Statins | Enhances lipid control when used with statin medications. |
While Saroglitazar 4 mg is generally well-tolerated, some individuals may experience mild side effects. These include:
Serious side effects are uncommon, but if you notice signs like yellowing of the skin or eyes, dark urine, unusual fatigue, or persistent abdominal pain, seek medical help immediately.
It’s important to inform your doctor of any existing medical conditions and current medications to avoid interactions or complications. Periodic blood tests are advised to monitor liver function and lipid levels.
Always consult your healthcare provider before starting or stopping any medication, especially one like Saroglitazar, which affects multiple metabolic pathways.
Yes, Saroglitazar is often prescribed alongside statins for enhanced lipid control.
Duration depends on your condition. Most treatments last several months or more, as advised by your doctor.
Yes, it has shown benefits in NAFLD and NASH but requires monitoring.
It is generally weight-neutral, unlike some other antidiabetic medications.
Sorry! Saroglitazar 4 mg Is Out Of Stock.
Please click below to view other similar medications.
Declan Pattison
April 14, 2025Excellent for managing my lipids and sugar levels.”
Reply